M Hallek

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. doi request reprint Therapy of chronic lymphocytic leukaemia
    Michael Hallek
    Klinik I fur Innere Medizin, Center for Integrated Oncology Köln Bonn, Universitat zu Koln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Best Pract Res Clin Haematol 23:85-96. 2010
  2. doi request reprint Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles
    Stefanie Stahnke
    Department I of Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Virology 409:77-83. 2011
  3. doi request reprint Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
    Michael Hallek
    Department I of Internal Medicine, University of Cologne, Center for Integrated Oncology Köln Bonn, Center of Excellence on Cellular Stress Responses in Aging Associated Diseases, Kerpener Strasse 62, Koln, Germany
    Am J Hematol 88:803-16. 2013
  4. pmc A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report
    Cristiano Krings Rocha
    Department I of Internal Medicine, University at Cologne, Cologne, Germany
    Mol Cytogenet 4:8. 2011
  5. ncbi request reprint Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia
    Michael Hallek
    Klinik I fur Innere Medizin, Universitat zu Koln, Koln, Germany
    Hematol J 5:S20-30. 2004
  6. doi request reprint Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    M Hallek
    Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany
    Lancet 376:1164-74. 2010
  7. doi request reprint State of the art treatment of chronic lymphocytic leukaemia
    Michael Hallek
    Klinik I fur Innere Medizin, German CLL Study Group, University of Cologne, Kerpener Strasse 62, 50937 Koln, Germany
    Blood Rev 25:1-9. 2011
  8. ncbi request reprint Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment
    M Hallek
    Klinik I fur Innere Medizin, Universitat Koln, Germany
    Onkologie 27:97-104. 2004
  9. ncbi request reprint [Aging and internal medicine]
    M Hallek
    Medizinische Klinik I, Universitätsklinikum zu Köln, Joseph Stelzmann Strasse 9, 50924, Koln, Deutschland
    Internist (Berl) 48:1189. 2007
  10. pmc Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    Michael Hallek
    Klinik I fur Innere Medizin, Universitat zu Koln, Koln, Germany
    Blood 111:5446-56. 2008

Detail Information

Publications83

  1. doi request reprint Therapy of chronic lymphocytic leukaemia
    Michael Hallek
    Klinik I fur Innere Medizin, Center for Integrated Oncology Köln Bonn, Universitat zu Koln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Best Pract Res Clin Haematol 23:85-96. 2010
    ..This review attempts to summarise the current use of these different modalities in CLL therapy...
  2. doi request reprint Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles
    Stefanie Stahnke
    Department I of Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Virology 409:77-83. 2011
    ..Furthermore, co-infection with endosomolytically active, but not with inactive adenoviral variants partially rescued (76)HD/AN, providing the first evidence for a function of this domain in endosomal escape of incoming AAV particles...
  3. doi request reprint Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
    Michael Hallek
    Department I of Internal Medicine, University of Cologne, Center for Integrated Oncology Köln Bonn, Center of Excellence on Cellular Stress Responses in Aging Associated Diseases, Kerpener Strasse 62, Koln, Germany
    Am J Hematol 88:803-16. 2013
    ..The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells...
  4. pmc A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report
    Cristiano Krings Rocha
    Department I of Internal Medicine, University at Cologne, Cologne, Germany
    Mol Cytogenet 4:8. 2011
    ..This case underlines the importance of cytogenetic analyses especially in atypical cases of B cell lymphomas...
  5. ncbi request reprint Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia
    Michael Hallek
    Klinik I fur Innere Medizin, Universitat zu Koln, Koln, Germany
    Hematol J 5:S20-30. 2004
    ....
  6. doi request reprint Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    M Hallek
    Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany
    Lancet 376:1164-74. 2010
    ....
  7. doi request reprint State of the art treatment of chronic lymphocytic leukaemia
    Michael Hallek
    Klinik I fur Innere Medizin, German CLL Study Group, University of Cologne, Kerpener Strasse 62, 50937 Koln, Germany
    Blood Rev 25:1-9. 2011
    ..Finally, the development of new biological markers that describe distinct forms of CLL allows to enter the era of personalized therapy similar to other malignancies...
  8. ncbi request reprint Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment
    M Hallek
    Klinik I fur Innere Medizin, Universitat Koln, Germany
    Onkologie 27:97-104. 2004
    ..It is anticipated that these questions will be answered over the coming few years by including patients in multicentre studies like those being carried out by the German CLL study group...
  9. ncbi request reprint [Aging and internal medicine]
    M Hallek
    Medizinische Klinik I, Universitätsklinikum zu Köln, Joseph Stelzmann Strasse 9, 50924, Koln, Deutschland
    Internist (Berl) 48:1189. 2007
  10. pmc Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    Michael Hallek
    Klinik I fur Innere Medizin, Universitat zu Koln, Koln, Germany
    Blood 111:5446-56. 2008
    ..This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice...
  11. doi request reprint Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    J J Vehreschild
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 68:987-95. 2012
    ..To estimate the pharmacokinetic (PK) properties of posaconazole in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing chemotherapy in a clinical setting...
  12. doi request reprint Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies
    B J Liss
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    Infection 40:613-9. 2012
    ....
  13. doi request reprint Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
    J J Vehreschild
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Koln, Germany
    J Antimicrob Chemother 65:1466-71. 2010
    ..However, the value of prophylaxis has been questioned in centres with a low incidence of invasive fungal diseases (IFDs) and pre-emptive treatment strategies...
  14. doi request reprint [Hematology 2008]
    P Borchmann
    Klinik I fur Innere Medizin, Universitatsklinikum, Joseph Stelzmann Str 9, 50924 Köln
    Dtsch Med Wochenschr 133:1400-4. 2008
  15. doi request reprint [Neutropenia and sepsis]
    M Kochanek
    Internistische Intensivstation, Klinik I fur Innere Medizin, Universitätsklinikum Köln, Kerpener Str 62, 50937 Koln, Deutschland
    Internist (Berl) 54:1061-9. 2013
    ..Thus, crucial for the diagnosis and therapy of neutropenic sepsis are clear and well-communicated algorithms, rapid action, and close collaboration between oncologists and intensivists. ..
  16. doi request reprint [Multimodality therapy of colorectal cancer]
    U Hacker
    Klinik I fur Innere Medizin, Centrum für Integrierte Onkologie Köln Bonn, Universitat zu Koln, Joseph Stelzmann Straße 9, 50924, Koln
    Internist (Berl) 51:1366-73. 2010
    ....
  17. doi request reprint Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma
    Roland Schnell
    Department I of Internal Medicine, University of Cologne, Germany
    Onkologie 31:49-51. 2008
    ..Thus, only very limited data of cHL patients treated with anti- CD20 immunoconstructs are available. To date, none of the patients treated with 90Y ibritumomab tiuxetan demonstrated any response...
  18. ncbi request reprint A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
    Elke Pogge Von Strandmann
    Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Blood 107:1955-62. 2006
    ..The use of recombinant NK receptor ligands that target NK cells to tumor cells might offer new approaches for other malignancies provided a tumor antigen-specific antibody is available...
  19. doi request reprint A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation
    Kai Hubel
    University Hospital Cologne, Klinik I fur Innere Medizin, Stem Cell Transplant Program, Kerpener Str 62, 50937 Cologne, Germany
    Transpl Immunol 23:215-9. 2010
    ..Levels of sCD30 decreased if patients responded to aGvHD-therapy. We suggest a potential role of sCD30 serum levels in prediction of aGvHD following allogeneic stem cell transplantation...
  20. doi request reprint An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)
    Norma Jung
    Department I of Internal Medicine, University of Cologne, Kerpener Str 62, 50935 Cologne, Germany
    Clin Rheumatol 29:1169-73. 2010
    ....
  21. ncbi request reprint Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
    Holger Schulz
    Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 99:706-14. 2007
    ....
  22. doi request reprint [Intensive care management of hematological and oncological patients]
    M von Bergwelt-Baildon
    Klinik I fur Innere Medizin, Universitätsklinikum Köln und Centrum für Integrierte Onkologie Köln Bonn, Kerpener Str 62, 50937 Koln, Deutschland
    Internist (Berl) 54:1080-6. 2013
    ..Therefore, the development of an interdisciplinary algorithm by oncologists and intensivists remains an important and dynamic challenge. ..
  23. pmc Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    T Hoehler
    Department I of Internal Medicine, Prosper Hospital Recklinghausen, 44879 Recklinghausen, Germany
    Br J Cancer 109:1408-13. 2013
    ..This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer...
  24. pmc Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin's abscess
    N Jung
    Department I of Internal Medicine, University of Cologne, 50935 Cologne, Germany
    Infect Dis Obstet Gynecol 2008:491401. 2008
    ..Sporadic severe infectious complications after incision of Bartholin's abcesses have been described but involvement of S. aureus is rare...
  25. doi request reprint [Morbidity and mortality conferences in internal medicine--experience at the University Hospital of Cologne]
    I Suarez
    Klinik I für Innere Medizin der Uniklinik Köln, Koln, Germany
    Dtsch Med Wochenschr 138:655-7. 2013
    ..The uncovering of structural problems frequently leads to direct improvements in patient care. Furthermore, the conference can play an important role in medical education...
  26. ncbi request reprint Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany
    A Hamprecht
    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany
    Euro Surveill 17:20262. 2012
    ..This case underscores the need for monitoring azole resistance in Aspergillus spp. and for routine susceptibility testing of moulds...
  27. pmc Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
    V Goede
    Department of Internal Medicine I, Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Kerpener Straße 62, Cologne 50924, Germany
    Br J Cancer 103:1407-14. 2010
    ..However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its role as a biomarker in metastatic CRC...
  28. ncbi request reprint Fludarabine in chronic lymphocytic leukaemia
    Thomas Elter
    First Department of Internal Medicine, University of Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Expert Opin Pharmacother 7:1641-51. 2006
    ....
  29. doi request reprint [Tyrosin kinase inhibitors in oncology]
    T Zander
    Centrum für Integrierte Onkologie Köln Bonn, Klinik I fur Innere Medizin, Universitätsklinik Köln, Kerpenerstrasse 62, Koln, Germany
    Internist (Berl) 52:595-600. 2011
    ..An intense interaction between clinical science in clinical trials, preclinical research and excellent molecular quality controlled diagnostics is crucial for the further development...
  30. doi request reprint Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up
    B Eichhorst
    Department of Internal Medicine I, University of Koln, Koln, Germany
    Ann Oncol 19:ii60-2. 2008
  31. doi request reprint [Oncology and palliative medicine]
    J Gartner
    Zentrum für Palliativmedizin, Uniklinik Köln, Kerpener Straße 62, 50924, Koln
    Internist (Berl) 52:15-6, 18-9. 2011
    ....
  32. doi request reprint [Thrombotic-thrombocytopenic purpura]
    M Hellmann
    Klinik I fur Innere Medizin, Universitätsklinikum Köln, Kerpener Straße 62, 50937 Koln, Deutschland
    Internist (Berl) 51:1136, 1138-44. 2010
    ..The monoclonal CD20 antibody rituximab targets ADAMTS13 antibody production and has the potential to be an effective therapy for relapsed TTP or initial treatment to shorten duration of plasma exchange...
  33. doi request reprint Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
    Carmen D Schweighofer
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Br J Haematol 144:95-8. 2009
    ..004). Minimal residual disease (MRD) levels were persistently reduced after consolidation. Therefore, despite toxicity, MRD reduction by alemtuzumab consolidation translates into a significantly improved long-term clinical outcome...
  34. ncbi request reprint Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
    Thomas Elter
    Department of Hematology and Oncology, University of Cologne, Cologne, Germany
    J Clin Oncol 23:7024-31. 2005
    ..To determine the efficacy and safety of a newly developed concomitant administration of fludarabine and alemtuzumab (FluCam) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL)...
  35. ncbi request reprint Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy
    Barbara F Eichhorst
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    Br J Haematol 136:63-72. 2007
    ....
  36. doi request reprint [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis]
    K Hubel
    Klinik I fur Innere Medizin, Uniklinik Köln, Kerpener Str 62, 50937, Koln, Deutschland
    Internist (Berl) 54:709-14. 2013
    ..The definition of high-risk and low-risk patients allows a tailored clinical management. This report provides information on the biology, risk stratification, diagnosis, and follow-up of patients with MGUS and MBL...
  37. ncbi request reprint Novel and emerging drugs for chronic lymphocytic leukemia
    S Isfort
    Department of Internal Medicine I, Center for Integrated Oncology Köln Bonn, Cluster of Excellence on Cellular Stress Responses in Aging associated Diseases CECAD Cologne, University of Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Curr Cancer Drug Targets 12:471-83. 2012
    ..This article reviews novel drugs that were recently developed for the use in CLL. The agents discussed in this article were selected for having already shown preliminary evidence of clinical activity...
  38. doi request reprint Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis
    S Uhrig
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Gene Ther 19:210-8. 2012
    ....
  39. doi request reprint Prognostic factors in chronic lymphocytic leukemia
    M Hallek
    Klinik I fur Innere Medizin, Universitat zu Koln, Koln, Germany
    Ann Oncol 19:iv51-3. 2008
  40. pmc Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
    V Kohl
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 54:207-12. 2010
    ..Corresponding adjustments of the starting dose according to the presence of diarrhea and according to age appear to be justified before TDM results are available...
  41. ncbi request reprint Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells
    C P Pallasch
    Laboratory of Cellular Immunotherapy, Clinic I of Internal Medicine, University of Cologne, Cologne, Germany
    Leukemia 22:585-92. 2008
    ..003). In summary, alterations of lipid metabolism are involved in CLL pathogenesis and might represent a novel therapeutic target in CLL...
  42. ncbi request reprint [Elderly patients in clinical trials: new fitness-adapted concepts]
    V Goede
    Klinik I fur Innere Medizin, Universitätsklinikum Köln, 50924, Koln, Deutschland
    Internist (Berl) 48:1232-7. 2007
    ..The benefit of modifying a treatment regimen in medically unfit patients of advanced age has to be determined by separate trials...
  43. doi request reprint Determinants and implications of cancer patients' psychosocial needs
    N Ernstmann
    Center for Health Services Research Cologne, University of Cologne, 50933 Cologne, Germany
    Support Care Cancer 17:1417-23. 2009
    ....
  44. ncbi request reprint Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    Holger Schulz
    Clinic I of Internal Medicine, University of Cologne, Cologne 50924, Germany
    Blood 100:3115-20. 2002
    ..The median duration of response was 75 weeks. We conclude that the combination of rituximab and fludarabine is feasible and effective in patients with B-CLL...
  45. doi request reprint The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo
    Julian Paesler
    Department I of Internal Medicine, University at Cologne, Cologne, Germany
    Clin Cancer Res 16:3390-8. 2010
    ..We investigated the efficacy and selectivity of both compounds in CLL cells, simulated potential combination with conventional cytostatics, and tested the effect of both substances on CLL-like tumor xenografts...
  46. ncbi request reprint Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
    Barbara F Eichhorst
    Department of Internal Medicine I, University of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Blood 107:885-91. 2006
    ..In summary, first-line treatment with FC increases the response rates and the treatment-free interval in younger patients with advanced CLL...
  47. doi request reprint Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?
    Thomas Elter
    Department of Hematology and Oncology, University of Cologne, Cologne, Germany
    Int J Hematol 90:199-204. 2009
    ..Furthermore, this study was initiated as the groundwork for a large phase III randomised trial...
  48. doi request reprint First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
    Barbara F Eichhorst
    Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany
    Blood 114:3382-91. 2009
    ..This trial is registered with www.isrctn.org under identifier ISRCTN 36294212...
  49. pmc Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo
    Rajesh Kumar Gandhirajan
    Department I of Internal Medicine I, University at Cologne, Cologne, Germany
    Neoplasia 12:326-35. 2010
    ..We therefore hypothesize that antagonism of lef-1 might lead to killing of CLL cells. We used two small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling (CGP049090 and PKF115-584) to test our hypothesis...
  50. doi request reprint Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade
    Christian P Pallasch
    Laboratory of Cellular Immunotherapy, Clinic I of Internal Medicine, University of Cologne, Germany
    Leuk Res 33:460-4. 2009
    ..04). In summary, CD200 blockade may provide therapeutic benefits in CLL by augmenting an antigen-specific T cell response with suppression of regulatory T cells...
  51. doi request reprint Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease
    Christian Philipp Pallasch
    Laboratory of Cellular Immunotherapy, Clinic I of Internal Medicine, University of Cologne, Cologne, Germany
    Blood 112:4213-9. 2008
    ..Both association with unmutated IgV(H) and the specific induction of TOSO via the BCR suggest autoreactive BCR signaling as a key mediator of apoptosis resistance in CLL...
  52. ncbi request reprint Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group
    Barbara F Eichhorst
    Department of Internal Medicine I, University of Cologne, Cologne, Germany
    J Clin Oncol 25:1722-31. 2007
    ..Therefore, the German CLL Study Group assessed HRQOL in younger patients with advanced CLL receiving first-line chemotherapy with fludarabine or fludarabine plus cyclophosphamide (FC)...
  53. doi request reprint The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes
    Aditya Veldurthy
    Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
    Blood 112:1443-52. 2008
    ..002). In summary, dasatinib shows potent inhibitory effects on the survival of CLL cells in vitro, most prominently in samples obtained from patients with unfavorable prognostic features...
  54. ncbi request reprint Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
    Marc Beyer
    Molecular Tumor Biology and Tumor Immunology Clinic I for Internal Medicine, University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50931 Cologne, Germany
    Blood 106:2018-25. 2005
    ..In light of similar findings for cyclophosphamide the combination of fludarabine and cyclophosphamide might be further exploited in strategies reducing immunosuppression prior to cancer immunotherapy...
  55. ncbi request reprint Physiologic evaluation in the elderly prior to treatment with chemotherapy
    Michael Hallek
    Clinic I for Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Clin Adv Hematol Oncol 5:620-1. 2007
  56. doi request reprint Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors
    Natascha K Schuhmann
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Exp Hematol 38:707-17. 2010
    ..This is relevant for application in regenerative medicine of ischemic tissues, where transient transgene expression is likely sufficient to achieve therapeutic benefits...
  57. ncbi request reprint Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency
    Ulrich T Hacker
    Klinik fur Innere Medizin I, Klinikum der Universität zu Köln, Joseph Stelzmann Strasse 9, 50925 Köln, Germany
    J Gene Med 7:1429-38. 2005
    ..Different adeno-associated virus (AAV) serotypes have been characterized so far, which show considerable differences in tissue tropism. Consequently, we aimed to characterize the most efficient serotype for this application...
  58. doi request reprint Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab
    Jens Marcus Chemnitz
    Department I of Internal Medicine, University of Cologne, Germany
    Ann Hematol 89:1029-33. 2010
    ..In conclusion, rituximab represents an effective second-line treatment option in relapsing or refractory TTP. Still, patients need to be closely monitored for relapses with extended follow-up...
  59. ncbi request reprint A cost calculation model for specialist palliative care for patients with non-small cell lung cancer in a tertiary centre
    Christoph Ostgathe
    Department of Palliative Medicine, University of Cologne, Cologne, Germany
    Support Care Cancer 16:501-6. 2008
    ..In this paper, we describe methodical and financial aspects of prospective pricing of palliative care within a concept of integrated care for patients with NSCLC in Germany...
  60. doi request reprint Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Thomas Elter
    Department of Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Ann Hematol 88:121-32. 2009
    ..In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL. We also discuss recommendations for effectively monitoring and managing infections in CLL patients...
  61. ncbi request reprint Pharmacokinetics of alemtuzumab and the relevance in clinical practice
    Thomas Elter
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    Leuk Lymphoma 49:2256-62. 2008
    ..Future studies are needed to improve the PK model of alemtuzumab and to explore a PK-guided dosing schedule, with the goal of maximising the therapeutic benefit of this agent...
  62. ncbi request reprint Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes
    Christine Mayr
    Klinische Kooperationsgruppe Gene Therapy, Munich, Germany
    Blood 105:1566-73. 2005
    ..In summary, FMOD was shown for the first time to be naturally processed and presented as TAA in primary CLL cells, enabling the expansion of autologous tumor-specific T cells...
  63. ncbi request reprint Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity
    Ulrich T Hacker
    Gene Center, Ludwig Maximilian University Munich, Feodor Lynen Strasse 25, 81377 Munich, Germany
    Cancer Immunol Immunother 55:547-57. 2006
    ..Our results show the importance of monitoring gene transfer in the whole tumour cell population, especially for the evaluation of in vivo therapies targeted to heterogeneous tumour cell populations...
  64. ncbi request reprint Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
    Zoltan A Nagy
    GPC Biotech AG, Martinsried Munich, Germany
    Nat Med 8:801-7. 2002
    ..Such monoclonal antibodies offer the potential for a novel therapeutic approach to lymphoid malignancies...
  65. ncbi request reprint Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
    Christine Mayr
    Gesellschaft für Strahlenforschung GSF National Research Center for Environment and Health, Munich, Germany
    Blood 107:742-51. 2006
    ..Our data may facilitate the identification of molecular events crucial for transforming activity in this disease and should have implications for risk-adapted clinical management of patients with CLL...
  66. ncbi request reprint Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia
    Barbara Schmitt
    Klinikum der Ludwig Maximilians Universität, Munich, Germany
    Clin Lymphoma 3:26-35. 2002
    ..It remains to be shown whether patients with CLL achieve improved overall survival with these combination chemotherapies...
  67. ncbi request reprint Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells
    Elke Pogge von Strandmann
    Department of Internal Medicine I, University Hospital of Cologne, Kerpener Str 62, D 50924 Cologne, Germany
    Immunity 27:965-74. 2007
    ..These data identify BAT3 as a cellular ligand for NKp30. We propose a concept for target cell recognition by NK cells beyond "missing self" and "induced self," mediated through a tumor cell-derived extracellular factor...
  68. ncbi request reprint Future prospects for alemtuzumab (MabCampath)
    Kanti Rai
    Long Island Jewish Medical Center New Hyde Park, NY 11042, USA
    Med Oncol 19:S57-63. 2002
    ....
  69. ncbi request reprint Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid
    Nadja A Huttner
    Gene Center of the Ludwig Maximilians University Munich, Feodor Lynen Str 25, 81377 Munich, Germany
    J Gene Med 5:120-9. 2003
    ..One of the most promising features is the ability of wild-type (wt) AAV to integrate site-specifically into human chromosome 19. However, this feature is lost in rAAV vectors due to the removal of the rep-coding sequences...
  70. ncbi request reprint Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
    Michael Stanglmaier
    Clinical Cooperation Group for Gene Therapy, GSF National Institute of Health and Environment, Marchioninistr 25, 81377, Munich, Germany
    Ann Hematol 83:634-45. 2004
    ....
  71. ncbi request reprint Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52
    Michael Keating
    Med Oncol 19:S1-2. 2002
  72. ncbi request reprint AAV-based gene transfer
    Hildegard Buning
    Laboratorium für Molekulare Biologie Genzentrum Ludwig Maximilians Universität München 81377 München Germany
    Curr Opin Mol Ther 5:367-75. 2003
    ..Here, we highlight recent developments to suggest that AAV vectors will play a key role in the future deployment of genetic medicine in humans...
  73. ncbi request reprint The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate
    Christine Schuster
    Klinische Kooperationsgruppe Gentherapie, GSF National Research Institute for Environment and Health, Munich, Germany
    Blood 101:655-63. 2003
    ....
  74. ncbi request reprint Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation
    Ulrich Wahl
    GSF Institut für Molekulare Immunologie, Marchioninistrasse 25, D 81377 Munich, Germany
    Clin Cancer Res 9:4240-6. 2003
    ..The induction of autologous tumor-specific T lymphocytes in the presence of trioma and antigen-presenting cells was examined in vitro by determining cytokine secretion in coculture assays...
  75. ncbi request reprint Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy
    Bernd Koppold
    Department of Obstetrics and Gynecology, University of Ulm Medical School, Frauensteige 14, 89075, Ulm, Germany
    J Cancer Res Clin Oncol 132:787-94. 2006
    ..Furthermore, the capacity of tumor cells expressing transgenic CD40 ligand (CD40L) to stimulate dendritic cells was measured...
  76. ncbi request reprint Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
    Christoph Schmid
    Department of Internal Medicine III, José Carreras Unit for Hematopoietic Stem Cell Transplantation, Ludwig Maximilians University Hospital, Marchioninistr 15, 81379 Munich, Germany
    Blood 108:1092-9. 2006
    ..007; HR = 3.01 [OS]; P = .002; HR = 3.25 [LFS]). These results indicate a high activity of the regimen in refractory AML...
  77. ncbi request reprint Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia
    Thomas Allgeier
    GSF Institut für Molekulare Immunologie, Marchioninistr 25, D 81377 Munchen, Germany
    Cancer Lett 245:275-83. 2007
    ..It should be considered that FACS analysis is not sufficient to assess fusion frequencies and that interactions between unfused DC and CLL cells also result in PBMC activation...
  78. ncbi request reprint Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
    Jacques Louis Binet
    Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093 0663, USA
    Blood 107:859-61. 2006
    ..Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group...
  79. ncbi request reprint CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes
    Dagmar Bund
    KKG Gene Therapy, GSF National Research Center for Environment and Health, Munich, Germany
    Exp Hematol 35:920-30. 2007
    ..CD23 is constitutively and atypically expressed on malignant B cells in patients with chronic lymphocytic leukemia (B-CLL). Here, we investigated whether CD23-derived peptides might function as B-CLL-specific tumor-associated antigen (TAA)...
  80. ncbi request reprint Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts?
    Michael Hallek
    Onkologie 28:387. 2005
  81. pmc Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking
    Kerstin Lux
    Genzentrum, LMU Munchen, Munich, Germany
    J Virol 79:11776-87. 2005
    ..Moreover, our findings argue against an efficient nuclear entry mechanism of intact AAV capsids and favor the occurrence of viral uncoating before or during nuclear entry...
  82. ncbi request reprint Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector
    Bernd Koppold
    University of Ulm Medical School, Department of Obstetrics and Gynecology, Ulm, Germany
    Int J Oncol 26:95-101. 2005
    ....
  83. ncbi request reprint Report on the 1st international workshop of the german competence network malignant lymphomas
    Daniel Re
    Department of Internal Medicine I, University Hospital of Cologne, Germany
    Onkologie 30:265-73. 2007
    ..This report summarizes novel aspects of pathogenesis and targeted approaches, maintenance therapy, management of the elderly patients, and the use of positron emission tomography for clinical decision making...